KLP Kapitalforvaltning AS Invests $12.32 Million in IQVIA Holdings Inc. (NYSE:IQV)

KLP Kapitalforvaltning AS acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 62,675 shares of the medical research company's stock, valued at approximately $12,316,000.

Other institutional investors have also recently bought and sold shares of the company. Synergy Asset Management LLC bought a new stake in shares of IQVIA in the 4th quarter worth about $33,000. Avior Wealth Management LLC increased its stake in shares of IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company's stock valued at $38,000 after acquiring an additional 87 shares during the last quarter. Lee Danner & Bass Inc. bought a new position in shares of IQVIA during the 4th quarter valued at about $44,000. Versant Capital Management Inc lifted its position in IQVIA by 46.0% in the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock valued at $58,000 after acquiring an additional 93 shares in the last quarter. Finally, SBI Securities Co. Ltd. bought a new position in shares of IQVIA in the 4th quarter valued at about $60,000. Institutional investors own 89.62% of the company's stock.

IQVIA Stock Down 0.7 %

NYSE:IQV traded down $1.32 during trading hours on Thursday, hitting $178.70. 444,319 shares of the company traded hands, compared to its average volume of 1,241,241. IQVIA Holdings Inc. has a one year low of $177.10 and a one year high of $253.84. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The company has a market cap of $31.51 billion, a PE ratio of 23.84, a PEG ratio of 1.99 and a beta of 1.50. The firm's 50-day simple moving average is $193.92 and its 200-day simple moving average is $207.10.

Remove Ads

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on IQV. Royal Bank of Canada restated an "outperform" rating and set a $270.00 target price on shares of IQVIA in a research note on Monday, February 10th. Robert W. Baird decreased their target price on IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 21st. Citigroup dropped their price target on IQVIA from $225.00 to $210.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. BTIG Research lowered IQVIA from a "buy" rating to a "neutral" rating in a report on Monday, February 3rd. Finally, Barclays decreased their price target on shares of IQVIA from $255.00 to $235.00 and set an "overweight" rating on the stock in a research note on Monday, February 3rd. Five investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $249.05.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.